argenx SE (ARGX)

Currency in EUR
815.40
-26.20(-3.11%)
Closed·

ARGX Earnings

Latest Release
Jul 23, 2026
EPS / Forecast
6.44 / 5.54
Revenue / Forecast
1.36B / 1.26B
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/09--/6.57--/1.42B----Free Sign Up
2026/066.44/5.541.36B/1.26B+16.25%+7.94%Free Sign Up
2026/034.69/4.581.11B/1.13B+2.4%-1.77%Free Sign Up
2025/126.80/5.071.12B/1.10B+34.12%+1.82%Free Sign Up
2025/094.48/3.72995.62M/909.63M+20.43%+9.45%Free Sign Up
2025/063.27/2.62845.04M/759.90M+24.81%+11.2%Free Sign Up
2025/032.29/2.11715.91M/736.66M+8.53%-2.82%Free Sign Up
2024/1211.32/1.65731.03M/668.56M+586.06%+9.34%Free Sign Up
2024/091.28/0.127542.42M/494.15M+911.06%+9.77%Free Sign Up
2024/060.415/0.410450.86M/450.86M+1.1%0%Free Sign Up

All numbers in EUR

argenx SE Earnings Call Summary for Q2/2026

  • argenx reported Q2 2026 product sales of $1.5B, up 60% YoY and 17% QoQ, with U.S. sales reaching $1.3B driven by VYVGART growth.
  • Operating profit surged 146% YoY to $494M; cash position strengthened to $5.2B, up $744M since year-start, supporting pipeline investments.
  • VYVGART became first treatment approved across all gMG serotypes; company targets advancing five late-stage molecules by 2030.
  • Key catalysts include myositis data in Q3 2026, empasiprubart MMN readout in Q4 2026, and auto-injector launch planned for 2027.
  • Stock rose 1.95% to $773.20 in premarket; management emphasized sustained margin expansion and earnings growth amid 18 consecutive growth quarters.
Last Updated: 2026-07-23, 09:50 a/m
Read Full Transcript

FAQ

What Is Argenx's Earnings Per Share (TTM)?

The Argenx EPS (TTM) is 26.21.

When Is The Next Argenx Earnings Date?

Argenx will release its next earnings report on Oct 22, 2026.

What Is Argenx’s Revenue Forecasts For Upcoming Quarters?

Argenx’s revenue forecast is 1.42B.

How Did Argenx React to the Company's Latest Earnings Report?

Argenx reported a +16.25% EPS surprise and a +7.94% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by 6.07%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.